Literature DB >> 8204473

Increased plasma activity of plasminogen activator inhibitor 1 (PAI-1) in two patients with Klinefelter's syndrome complicated by leg ulcers.

J C Veraart1, K Hamulyak, H A Neumann, J Engelen.   

Abstract

Klinefelter's syndrome is the most frequent major abnormality of sexual differentiation in men with two or more X-chromosomes, and affects one in 500 males. The syndrome is characterized by eunuchoid body proportions, scanty facial and body hair, gynaecomastia, and small firm testes. Leg ulcers, especially in combination with hyperpigmentation, have been reported in association with Klinefelter's syndrome. Thromboembolic processes are also frequently observed. The leg ulcers in patients with Klinefelter's syndrome are usually attributed to venous insufficiency. We describe two patients with Klinefelter's syndrome associated with recurrent ulcers and hyperpigmentation on both legs, in whom no venous or other underlying cause could be found. The patients were not taking any drugs, in particular no supplemental androgen therapy. Both had normal plasma testosterone values. We detected increased activity of plasminogen activator inhibitor 1 (PAI-1), with only a partial decrease upon venous occlusion. A possible role for this inhibitor of fibrinolysis in the pathogenesis of ulceration is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204473     DOI: 10.1111/j.1365-2133.1994.tb13112.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  2 in total

1.  Improvement of venous leg ulcers with androgen replacement therapy in a patient with undiagnosed klinefelter syndrome.

Authors:  Shwetha Thukuntla; Pratima Kumar
Journal:  Dermatoendocrinol       Date:  2011-10-01

2.  A Case Report of Exacerbation of Leg Ulcers Associated with Acute High-dose Acetylsalicylic Acid in a Patient with Klinefelter Syndrome.

Authors:  Lena Arizanovic; Snezana Spasic; Cedo Miljevic; Mihajlo B Spasic; Milan Nikolic
Journal:  Cureus       Date:  2019-12-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.